Stem definition | Drug id | CAS RN |
---|---|---|
779 | 17230-88-5 |
Dose | Unit | Route |
---|---|---|
0.60 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 33.78 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 5.18 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 15.71 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.31 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 21, 1976 | FDA |
None
None
Source | Code | Description |
---|---|---|
ATC | G03XA01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Antigonadotropins and similar agents |
FDA EPC | N0000175824 | Androgen |
FDA MoA | N0000000146 | Androgen Receptor Agonists |
FDA CS | M0001109 | Androstanes |
CHEBI has role | CHEBI:50751 | anti-estrogen |
CHEBI has role | CHEBI:50837 | estrogen antagonist |
MeSH PA | D004965 | Estrogen Antagonists |
MeSH PA | D006727 | Hormone Antagonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Fibrocystic breast changes | indication | 27431007 | DOID:10354 |
Endometriosis | indication | 129103003 | |
Hereditary Angioedema Prevention | indication | ||
Gynecomastia | off-label use | 4754008 | DOID:12698 |
Menorrhagia | off-label use | 386692008 | |
Precocious puberty | off-label use | 400179000 | |
Migraine | contraindication | 37796009 | DOID:6364 |
Chronic heart failure | contraindication | 48447003 | |
Intermenstrual bleeding - irregular | contraindication | 64996003 | |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Angina pectoris | contraindication | 194828000 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Mixed hyperlipidemia | contraindication | 267434003 | |
Pregnancy, function | contraindication | 289908002 | |
Thromboembolic disorder | contraindication | 371039008 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Porphyria | contraindication | 418470004 | |
Carcinoma of female breast | contraindication | 447782002 |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Progesterone receptor | Nuclear hormone receptor | AGONIST | WOMBAT-PK | CHEMBL | |||||
Androgen receptor | Nuclear hormone receptor | AGONIST | UNKNOWN | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | Ki | 4.99 | DRUG MATRIX | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.16 | DRUG MATRIX | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 5.09 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.25 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.60 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 4.98 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 5.01 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5.42 | DRUG MATRIX | |||||
Glucocorticoid receptor | Nuclear hormone receptor | Ki | 5.71 | DRUG MATRIX | |||||
Beta-3 adrenergic receptor | GPCR | Ki | 4.89 | DRUG MATRIX | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 5.46 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.26 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 5.20 | DRUG MATRIX | |||||
Kappa-type opioid receptor | GPCR | Ki | 5.21 | DRUG MATRIX | |||||
Estrogen receptor | Nuclear hormone receptor | Ki | 5.29 | DRUG MATRIX | |||||
Cytochrome P450 2C9 | Enzyme | IC50 | 6.52 | DRUG MATRIX | |||||
Substance-K receptor | GPCR | Ki | 5.05 | DRUG MATRIX | |||||
Steryl-sulfatase | Enzyme | WOMBAT-PK | |||||||
Sex hormone-binding globulin | Secreted | Kd | 8.20 | CHEMBL | |||||
Mu-type opioid receptor | GPCR | Ki | 5.24 | DRUG MATRIX | |||||
Androgen receptor | Transcription factor | Ki | 8.10 | DRUG MATRIX | |||||
Progesterone receptor | Transcription factor | Ki | 7.47 | DRUG MATRIX |
ID | Source |
---|---|
D003613 | MESH_DESCRIPTOR_UI |
4018233 | VUID |
N0000146564 | NUI |
C0010961 | UMLSCUI |
D00289 | KEGG_DRUG |
87881000 | SNOMEDCT_US |
4018233 | VANDF |
002116 | NDDF |
605 | MMSL |
3102 | RXNORM |
126124009 | SNOMEDCT_US |
4533 | MMSL |
d00204 | MMSL |
CHEMBL1479 | ChEMBL_ID |
N29QWW3BUO | UNII |
2556 | INN_ID |
DB01406 | DRUGBANK_ID |
CHEBI:4315 | CHEBI |
6942 | IUPHAR_LIGAND_ID |
28417 | PUBCHEM_CID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1368 | CAPSULE | 100 mg | ORAL | ANDA | 10 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1369 | CAPSULE | 200 mg | ORAL | ANDA | 10 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1392 | CAPSULE | 50 mg | ORAL | ANDA | 10 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0633 | CAPSULE | 50 mg | ORAL | ANDA | 10 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0634 | CAPSULE | 100 mg | ORAL | ANDA | 10 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0635 | CAPSULE | 200 mg | ORAL | ANDA | 10 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-243 | CAPSULE | 200 mg | ORAL | ANDA | 11 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2298 | CAPSULE | 200 mg | ORAL | ANDA | 10 sections |